Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen
The aim of this study was to identify the first abnormalities of apolipoprotein B (apoB) metabolism in HIV-infected patients treated by antiretroviral therapy (ART) with protease inhibitors (PIs). The influence of ART on the metabolism of apoB in VLDL, IDL, and LDL was investigated in six patients r...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2003-09-01
|
| Series: | Journal of Lipid Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520337329 |
| _version_ | 1818602153166503936 |
|---|---|
| author | Jean Michel Petit Michel Duong Emmanuel Florentin Laurence Duvillard Pascal Chavanet Jean Marcel Brun Henri Portier Philippe Gambert Bruno Vergès |
| author_facet | Jean Michel Petit Michel Duong Emmanuel Florentin Laurence Duvillard Pascal Chavanet Jean Marcel Brun Henri Portier Philippe Gambert Bruno Vergès |
| author_sort | Jean Michel Petit |
| collection | DOAJ |
| description | The aim of this study was to identify the first abnormalities of apolipoprotein B (apoB) metabolism in HIV-infected patients treated by antiretroviral therapy (ART) with protease inhibitors (PIs). The influence of ART on the metabolism of apoB in VLDL, IDL, and LDL was investigated in six patients receiving dual nucleoside reverse transcriptase inhibitors (NRTIs) and PI, and in five patients receiving NRTI and nevirapine. None of the patients had lipodystrophy. The study was performed in the fed state. Each subject received an intravenous injection of a 0.7 mg·kg−1 bolus of l-[1-13C]leucine, immediately followed by a 16 h constant infusion at 0.7 mg·kg−1·h−1. The VLDL- and IDL-apoB concentrations were significantly higher in PI-treated patients compared to non-PI-treated patients. The VLDL-apoB and IDL-apoB production rates were markedly higher in PI-treated patients compared to non-PI-treated patients (54.5 ± 30.1 vs. 30.9 ± 8.4 mg·kg−1·d−1, P = 0.04; and 43.5 ± 20.0 vs. 18.7 ± 7.8 mg·kg−1·d−1, P = 0.04, respectively).In conclusion, our study shows that patients receiving ART with PI present altered metabolism of the VLDL-IDL-LDL chain compared with patients treated without PI. These data confirm that PI therapy is associated with a physiopathological mechanism for dyslipidemia in addition to the effect of lipodystrophy on lipid metabolism. |
| first_indexed | 2024-12-16T13:02:45Z |
| format | Article |
| id | doaj.art-78d4d7cc859b40a5a13ac1654a9bc5bc |
| institution | Directory Open Access Journal |
| issn | 0022-2275 |
| language | English |
| last_indexed | 2024-12-16T13:02:45Z |
| publishDate | 2003-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Lipid Research |
| spelling | doaj.art-78d4d7cc859b40a5a13ac1654a9bc5bc2022-12-21T22:30:47ZengElsevierJournal of Lipid Research0022-22752003-09-0144916921697Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimenJean Michel Petit0Michel Duong1Emmanuel Florentin2Laurence Duvillard3Pascal Chavanet4Jean Marcel Brun5Henri Portier6Philippe Gambert7Bruno Vergès8Laboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceLaboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceLaboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceLaboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceLaboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceLaboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceLaboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceLaboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceLaboratoire de Biochimie and Institut National de la Santé et de la Recherche Médicale U498, Hôpital Universitaire du Bocage, 21000 Dijon, France; Services d'Endocrinologie, Hôpital Universitaire du Bocage, 21000 Dijon, France; des Maladies Infectieuses, Hôpital Universitaire du Bocage, 21000 Dijon, FranceThe aim of this study was to identify the first abnormalities of apolipoprotein B (apoB) metabolism in HIV-infected patients treated by antiretroviral therapy (ART) with protease inhibitors (PIs). The influence of ART on the metabolism of apoB in VLDL, IDL, and LDL was investigated in six patients receiving dual nucleoside reverse transcriptase inhibitors (NRTIs) and PI, and in five patients receiving NRTI and nevirapine. None of the patients had lipodystrophy. The study was performed in the fed state. Each subject received an intravenous injection of a 0.7 mg·kg−1 bolus of l-[1-13C]leucine, immediately followed by a 16 h constant infusion at 0.7 mg·kg−1·h−1. The VLDL- and IDL-apoB concentrations were significantly higher in PI-treated patients compared to non-PI-treated patients. The VLDL-apoB and IDL-apoB production rates were markedly higher in PI-treated patients compared to non-PI-treated patients (54.5 ± 30.1 vs. 30.9 ± 8.4 mg·kg−1·d−1, P = 0.04; and 43.5 ± 20.0 vs. 18.7 ± 7.8 mg·kg−1·d−1, P = 0.04, respectively).In conclusion, our study shows that patients receiving ART with PI present altered metabolism of the VLDL-IDL-LDL chain compared with patients treated without PI. These data confirm that PI therapy is associated with a physiopathological mechanism for dyslipidemia in addition to the effect of lipodystrophy on lipid metabolism.http://www.sciencedirect.com/science/article/pii/S0022227520337329HIV protease inhibitornucleoside reverse transcriptase inhibitorantiretroviral therapymetabolism abnormalitiesapolipoprotein Bdyslipidemia |
| spellingShingle | Jean Michel Petit Michel Duong Emmanuel Florentin Laurence Duvillard Pascal Chavanet Jean Marcel Brun Henri Portier Philippe Gambert Bruno Vergès Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen Journal of Lipid Research HIV protease inhibitor nucleoside reverse transcriptase inhibitor antiretroviral therapy metabolism abnormalities apolipoprotein B dyslipidemia |
| title | Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen |
| title_full | Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen |
| title_fullStr | Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen |
| title_full_unstemmed | Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen |
| title_short | Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen |
| title_sort | increased vldl apob and idl apob production rates in nonlipodystrophic hiv infected patients on a protease inhibitor containing regimen |
| topic | HIV protease inhibitor nucleoside reverse transcriptase inhibitor antiretroviral therapy metabolism abnormalities apolipoprotein B dyslipidemia |
| url | http://www.sciencedirect.com/science/article/pii/S0022227520337329 |
| work_keys_str_mv | AT jeanmichelpetit increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen AT michelduong increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen AT emmanuelflorentin increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen AT laurenceduvillard increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen AT pascalchavanet increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen AT jeanmarcelbrun increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen AT henriportier increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen AT philippegambert increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen AT brunoverges increasedvldlapobandidlapobproductionratesinnonlipodystrophichivinfectedpatientsonaproteaseinhibitorcontainingregimen |